Associate Director Community Outreach- 🫁Thoracic Oncology, University of Miami @SylvesterCancer , 🇵🇷Boricua, Co-founder @KidsHelpingKidsSucceed
Miami, FL
Joined June 2012
- Tweets14.7K
- Following3K
- Followers8.5K
- Likes19.2K
Dr. Estela Rodriguez retweeted
1/
New study on something our patients experience but we do not always measure:
lung cancer stigma.
Among 850 patients with lung, breast, colorectal or prostate cancer, people with lung cancer reported higher stigma — especially internalized shame and social isolation.
@SclcSMASHERS @FDA @LUNGevity @lungoncdoc @StephenVLiu @HHorinouchi @g_mountzios @sands_jacob @LauraAlderMD @oncodaily @OncoAlert @Latinamd @LuisPaz_Ares @RManochakian @LuisRaezMD @triparnasen @LaurenByersMD @LungCancerEu @alissajcooper @BZhangMD @NaglaAKarimMD @Annechiangmd @IASLC @NCCN @ASCO #ESMO26 @larvol @tribeMDUS @sylvestercancer @oncbrothers @chinmay @Jani_Chinmay @colazagasti @openmedicineHQ @myesmo @openmedkate @openmedben @chadinabhan @YoungLungCancer @OncodailyLung @ClinicalLung #LCSM @LungPolicy @dan_morgxen @LAGurwitch
Dr. Estela Rodriguez retweeted
Barack Obama’s recent riffs about President Trump (“He’s got the White House looking like Saddam Hussein opened a Cheesecake Factory!”) and Trump’s rambling response (“I passed three cognitive tests. I’m the only President that agreed to take them. And they’re hard, you know? Obama—Obama couldn’t have passed it.”) underscored the split-screen reality of the midterm elections, Susan B. Glasser writes. “Two Presidents, two Americas. For ten endless years, our politics has been all about the vast gap that separates these two men, and the near-impossible task of trying to understand how a country that elected Obama twice could, so soon after, do the same for Trump. Watching them both on Wednesday night, toggling between screens and alternate universes as they shot barbs at each other, was a reminder of how very long we’ve been stuck in this loop.
“What’s different this time is a sense—and, until there are votes counted and races called, it’s just a sense—that real-world events have intervened to make this less of an intractably divided country and more of a place where at least some shared truths are still possible.” Glasser reflects on Obama, Trump, and the midterms that may see the country bridging its divides: newyorkermag.visitlink.me/62…
Dr. Estela Rodriguez retweeted
Thank you to Dr. Lidia Schapira (@l_schapira) of Stanford University for our afternoon keynote, Reimagining Cancer Survivorship: From Discovery to Delivery, Locally and Globally, and to Dr. @CarmenCalfa for moderating.
Learn more about our Sylvester Cancer Survivorship Symposium: spr.ly/6017BHUYVx.
Dr. Estela Rodriguez retweeted
1/7 🫁 What happens when a patient with stage III lung cancer starts neoadjuvant chemoimmunotherapy but can no longer undergo surgery?
MDT-BRIDGE, a new phase II study in Nature Medicine, addresses this important clinical dilemma.
@SclcSMASHERS @FDA @LUNGevity @lungoncdoc @StephenVLiu @HHorinouchi @g_mountzios @sands_jacob @LauraAlderMD @oncodaily @OncoAlert @Latinamd @LuisPaz_Ares @RManochakian @LuisRaezMD @triparnasen @LaurenByersMD @LungCancerEu @alissajcooper @BZhangMD @NaglaAKarimMD @Annechiangmd @IASLC @NCCN @ASCO #ESMO26 @larvol @tribeMDUS @sylvestercancer @oncbrothers @chinmay @Jani_Chinmay @colazagasti @openmedicineHQ @myesmo @openmedkate @openmedben @chadinabhan @YoungLungCancer @OncodailyLung @ClinicalLung #LCSM @LungPolicy @dan_morgxen @LAGurwitch
Dr. Estela Rodriguez retweeted
ASCO Election
The ASCO Nominating Committee has selected 11 distinguished members as candidates for open leadership positions within the Society.
ASCO encourages all eligible members to cast their ballots to choose new Society leaders. Eligible members are those who have been awarded and hold the degree of Doctor of Medicine, Doctor of Osteopathy, Doctor of Philosophy, Doctor of Pharmacy, Doctor of Medical Science, Doctor of Nursing Science, Doctor of Nursing Practice, or equivalent doctoral-level degree as determined by the Society and the Association, and who are in good standing as of October 13, 2026. Eligible members will earn a FASCO point for voting in the ASCO Election.
The voting period closes on Wednesday, December 2, 2026, at 3:00 PM Eastern Standard Time, USA. All ballots (online or paper) must be received by this time.
@iaslc #WCLC26 @oncoalert @oncodaily @larvol @tribeMDUS @sylvestercancer @oncbrothers @chinmay @Jani_Chinmay @latinamd @colazagasti @openmedicineHQ @asco @myesmo @openmedkate @openmedben @chadinabhan @YoungLungCancer @lungoncdoc @OncodailyLung @ClinicalLung #LCSM
Dr. Estela Rodriguez retweeted
The link between obesity and early-onset cancer.
A nationwide study of 6.3 million people, age 20-39, with no prior cancer, by BMI and waist circumference, with 11 year follow-up, in South Korea
acpjournals.org/doi/full/10.… @AnnalsofIM
Dr. Estela Rodriguez retweeted
We are all done with #ESMO26! 10+ studies that were on our radar and the updated data around them.
Out in the community settings, it’s tough to keep up with all that is happening here in the world of cancer (and this was just ONE conference). Really appreciate you all sharing the data and importantly your take around this: @OncoAlert @weoncologists @DrChoueiri @StephenVLiu @SuyogCancer @dr_yakupergun @drsarahsam @PTarantinoMD @GIMedOnc @BijoyTelivala @RenoHemonc @nlindenberg @jryckman3 @ErikaHamilton9 @myESMO @LorenzaRimassa 🙏🏽🙏🏽
2 wks to #ESMO26! Here’s a📝of🔑studies for GeneralOnc that could change/reinforce SoC:
- #INTerpath001
- #VOLGA
- #ANZUP1801
- #LITESPARK011
- #DeLLphi305
- #SAFFRON
- #CLARITYGastric01
- #MOIO
- #TroFuse005
- Breast Ca Updates
#OncTwitter @myESMO @OncoAlert
Dr. Estela Rodriguez retweeted
PANKU-Lung01 at #ESMO26: promising phase III results for EGFR×HER3 bispecific ADC iza-bren after EGFR TKI.
PFS: 11.1 vs 5.7 mo (HR 0.40).
ORR: 60.2% vs 34.5%.
OS immature. China-only trial; global validation and optimal sequencing remain important.
#LungCancer
🤖 Made with AI
Dr. Estela Rodriguez retweeted
#ESMO26 The brilliant Dr. @marinagarassino with biomarker analysis from the phase III KEYNOTE 671 study of perioperative pembrolizumab for resectable NSCLC showing association of T-cell inflamed gene expression profile and TMB with efficacy. Benefit across subgroups; inflamed profile associated with better prognosis. #ESMOAmbassadors
Dr. Estela Rodriguez retweeted
🔥NeoCOAST-2: ctDNA clearance & outcomes in resectable NSCLC
🆙 @Nature
☑Phase 2 platform; Arm 4 (Dato-DXd) highest ctDNA clearance (72.5%) & 24-mo EFS 77.9%
🎯ctDNA clearance → HR 0.22 for EFS (p<0.001)
🎯ctDNA clearance + pCR → EFS HR 0.10 (p=0.002)
🎙Dr. Lara McGrath @FordePatrick @MARIANOPROVENCI @DoctorJSpicer Dr. Tina Cascone
#LCSM @OncoAlert @Larvol
doi.org/10.1038/s41586-026-1…
Dr. Estela Rodriguez retweeted
#ESMO26 Dr. @fifimcdrmh presents the SARON trial. Phase II of consolidation radiotherapy vs systemic therapy in pts with driver negative oligometastatic NSCLC after 6-8w of control with systemic therapy. Improvement in PFS with radiation 13.9 vs 8.9m but no difference in OS.
Dr. Estela Rodriguez retweeted
🎯 #ESMO26 | Excellent discussion by @benlevylungdoc on SARON and PERSEE!
Two trials, two important lessons for advanced NSCLC.
🔹 SARON: Consolidative radiotherapy improved PFS and local disease control in oligo metastatic NSCLC, but no OS benefit (HR 0.99).
🔹 PERSEE: Pembrolizumab + chemo met its primary endpoint PFS but not OS though numerically better (not powered for OS) in PD-L1 ≥50% NSCLC.
Key messages from @benlevylungdoc :
• Oligometastatic disease needs better biological definition, beyond the number of lesions.
• Treatment intensification should be guided by better patient selection.
• More treatment does not automatically mean better outcomes!
- Lower threshold to add chemo to pembro in PD-L1 >50%
👏 A thoughtful discussion with practical implications for our clinics.
#ESMOAmbassador #LungCancer #NSCLC
Dr. Estela Rodriguez retweeted
‘New’ COCOON:
Reducing adverse events with Amivantamab/Lazertinib
👉 Simplified skin care regimen (x6m oral tetracycline, ceramide cream, oral zinc)
👉 Step up dosing: Lazer x4wks BEFORE Ami starts
✅ Combined approach reduces all grade dermatological adverse events (HR 0.31) @ 3m
✅ No Gr2+ cutaneous adverse events @ 4m
✅ Gr2+ scalp AE just 3%
🤔 I have no problem starting Lazer 1 month before Ami, if it makes combination much more tolerable. (With FLAURA2 we already start Osimertinib before chemo, whilst we wait for chemotherapy unit slot)
🤔 Need PFS data to make sure new COCOON does not impact on efficacy, but I doubt it will
🤔 Pragmatic way make this regimen easier, which is needed because it is challenging
#ESMO26 #LCSM
Dr. Estela Rodriguez retweeted
#ESMO26 New data on biomarker efficacy for #cMET #ADCs in both #EGFR WT and #EGFR mut pretreated patients:
➡️ IHC MET cut-off at 10% +++ for TemabA
➡️ Magnitude of benefit correlated with MET IHC for EGFR WT but was similar for
EGFRmut NSCLC
➡️Comparative efficacy of TemabA to Trop2 targeting ADCs
@myESMO #ESMOAmbassadors
Dr. Estela Rodriguez retweeted
“Prespecified descriptive OS analysis.” Those words should give us pause. Calling this a “positive OS result” in a phase 3 trial manuscript is misleading when OS was outside the formal testing strategy. The results are encouraging, but an OS benefit has not been formally demonstrated in this analysis.
I’m surprised this framing passed journal review. Oncologists and patients shouldn’t need to close-read a manuscript like English professors to understand whether a trial formally demonstrated an OS benefit. Put the bottom line up front.
@Timothee_MD @oncology_bg @SusanGKomen @BCRFcure @OncoAlert @Annals_Oncology @myESMO @ASCO @AACR @SABCSSanAntonio
📢 #ESMO26 concomitant paper - Overall survival with adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with high-risk HR+/HER2– early breast cancer: Six-year follow-up of the NATALEE trial.
🔗shorturl.at/AsvoB
@LoiSher
Dr. Estela Rodriguez retweeted
Excited for my first @FLASCO_ORG meeting: Women’s Cancer Care 💕
It feels extra special to be lecturing on Lung Cancer Prevention and Screening in the same session as my friends/colleagues @Latinamd @COlazagasti 🫁🤍
Congrats to program chair @Latinamd for a fantastic program💫
Dr. Estela Rodriguez retweeted
#ESMO26 Dr. Martin Sebastian presents PACE-LUNG: phase II study of osimertinib monotherapy for EGFR NSCLC with ctDNA at 3w and if positive, add 4 cycles of chemotherapy. 72/255 were ctDNA positive at 3w. mPFS 17.8m and OS 31.5m from start of osi - no comparator but encouraging.
Dr. Estela Rodriguez retweeted
🫁 Can early ctDNA clearance tell us which patients with EGFR-mutant NSCLC can avoid chemotherapy? FLAURA2 suggests not yet.
At ESMO 2026, serial plasma analysis from FLAURA2 showed remarkably similar EGFR mutation clearance with osimertinib + platinum-pemetrexed and osimertinib alone.
By week 2, 64% of patients in both groups had cleared detectable plasma EGFR mutations. By week 6, clearance reached 88% vs 89%.
Early clearance was prognostic, but it was not predictive. The PFS and OS benefits of osimertinib + chemotherapy were seen whether EGFR ctDNA cleared early or remained detectable.
That matters clinically. A rapid molecular response cannot currently be used to identify patients who can safely de-escalate to osimertinib alone.
The next step may require ultrasensitive multi-marker ctDNA assays capable of detecting molecular residual disease beyond simple EGFR mutation clearance.
oncodaily.com/oncolibrary/lu…
@AstraZeneca
#OncoDaily #OncoDailyLung #ESMO2026 #FLAURA2 #Osimertinib #EGFR #ctDNA #NSCLC
